UK Markets close in 1 hr 52 mins
  • FTSE 100

    7,351.89
    +11.99 (+0.16%)
     
  • FTSE 250

    23,225.18
    -12.99 (-0.06%)
     
  • AIM

    1,199.83
    -0.22 (-0.02%)
     
  • GBP/EUR

    1.1682
    -0.0065 (-0.55%)
     
  • GBP/USD

    1.3209
    -0.0033 (-0.2483%)
     
  • BTC-GBP

    37,931.41
    -1,093.11 (-2.80%)
     
  • CMC Crypto 200

    1,309.44
    +4.32 (+0.33%)
     
  • S&P 500

    4,685.64
    -1.11 (-0.02%)
     
  • DOW

    35,744.57
    +25.14 (+0.07%)
     
  • CRUDE OIL

    71.60
    -0.45 (-0.62%)
     
  • GOLD FUTURES

    1,783.00
    -1.70 (-0.10%)
     
  • NIKKEI 225

    28,860.62
    +405.02 (+1.42%)
     
  • HANG SENG

    23,996.87
    +13.21 (+0.06%)
     
  • DAX

    15,716.35
    -97.59 (-0.62%)
     
  • CAC 40

    7,043.07
    -22.32 (-0.32%)
     

Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

·4-min read

Investment to support Cardurion’s further evolution into a cardiovascular leader

BOSTON, October 27, 2021--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. ("Cardurion" or "the Company"), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity. Bain Capital joins existing investors, Takeda Pharmaceuticals and Polaris Partners, in supporting the evolution of Cardurion into a leading cardiovascular biotechnology company.

Based in Boston, Massachusetts and with facilities there and in Shonan, Japan, Cardurion’s mission is to transform the treatment of cardiovascular diseases by translating the science of cardiovascular signaling pathways into groundbreaking therapeutics. The Company’s innovative pipeline of cardiovascular drug candidates includes a PDE9 inhibitor and a CaMKII inhibitor program. The investment will support the thoughtful advancement of Cardurion’s pipeline, enable the Company to scale its team, and create an industry-leading platform.

"We could not be more excited to welcome Bain Capital as investors in this transformational milestone for Cardurion," said Peter Lawrence, Chief Executive Officer of Cardurion. "We have a shared vision to continue to build a world-class cardiovascular company pursuing treatments for a broad range of debilitating diseases. This funding will allow us to advance our first-in-class PDE9 inhibitor into a major Phase 2 trial in heart failure and to support the initiation of first-in-human studies with our CaMKII inhibitor program in several cardiovascular indications. We look forward to leveraging the experience and resources of our investors to build and scale Cardurion as a leading cardiovascular biotechnology company."

"This is an impressive team laser-focused on deep science, innovation, and collaboration in a strategically important therapeutic area where there is high unmet need for patients," said Adam Koppel, M.D., PhD, a Managing Director at Bain Capital Life Sciences. "We look forward to a lasting partnership with Mike and Peter and their team, supporting the efforts to identify and develop novel therapies while building out a scale platform that can serve as a champion for cardiovascular drug development."

"This investment will accelerate our progress as we work to create transformative new medicines that deliver value for patients and other key stakeholders," said Michael E. Mendelsohn, M.D., Founder and Chairman of Cardurion. "Cardurion is dedicated to advancing novel mechanisms that yield new treatments for cardiovascular disease, which remains the greatest cause of morbidity and mortality in our society."

In conjunction with Bain Capital’s investment, Koppel and Nicholas Downing, MD, a Principal at Bain Capital Life Sciences, will join the Cardurion Board of Directors.

About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Founded by physician-scientist Michael E. Mendelsohn, M.D., and built by a team of physician-scientists and industry leaders with extensive experience in cardiovascular science, drug development and business development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs to target major unmet needs in cardiovascular medicine. Cardurion Pharmaceuticals has facilities in Boston, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

About Bain Capital

Founded in 1984, Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with offices on four continents and deep experience in healthcare. Bain Capital manages approximately $150 billion across asset classes and leverages the firm’s shared platform to capture opportunities in strategic areas of focus. Bain Capital Private Equity (http://www.baincapitalprivateequity.com) has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive. A team of more than 275 investment professionals creates value for portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare. Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally. The team focuses on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005123/en/

Contacts

Media Contact:
Scott Lessne
Stanton
slessne@stantonprm.com
646-502-3569

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting